PortfoliosLab logoPortfoliosLab logo
BBIO vs. ANET
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BBIO vs. ANET - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Arista Networks, Inc. (ANET). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BBIO achieves a -11.92% return, which is significantly lower than ANET's 19.36% return.


BBIO

1D
-0.35%
1M
-0.03%
YTD
-11.92%
6M
-9.25%
1Y
74.44%
3Y*
61.48%
5Y*
1.89%
10Y*

ANET

1D
1.38%
1M
10.32%
YTD
19.36%
6M
21.14%
1Y
60.82%
3Y*
56.72%
5Y*
47.39%
10Y*
42.38%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BBIO vs. ANET - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
BBIO
BridgeBio Pharma, Inc.
-11.92%178.75%-32.03%429.79%-54.32%-76.54%102.88%27.22%
ANET
Arista Networks, Inc.
19.36%18.55%87.73%94.07%-15.58%97.89%42.86%-21.16%

Correlation

The correlation between BBIO and ANET is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Jun 28, 2019

0.26

Fundamentals

Market Cap

BBIO:

$13.12B

ANET:

$199.22B

EPS

BBIO:

-$3.76

ANET:

$2.92

PS Ratio

BBIO:

23.00

ANET:

20.53

Total Revenue (TTM)

BBIO:

$566.04M

ANET:

$9.71B

Gross Profit (TTM)

BBIO:

$538.20M

ANET:

$6.17B

EBITDA (TTM)

BBIO:

-$602.24M

ANET:

$4.21B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BBIO vs. ANET — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBIO
BBIO Risk / Return Rank: 8484
Overall Rank
BBIO Sharpe Ratio Rank: 8484
Sharpe Ratio Rank
BBIO Sortino Ratio Rank: 8181
Sortino Ratio Rank
BBIO Omega Ratio Rank: 8181
Omega Ratio Rank
BBIO Calmar Ratio Rank: 8787
Calmar Ratio Rank
BBIO Martin Ratio Rank: 8787
Martin Ratio Rank

ANET
ANET Risk / Return Rank: 7474
Overall Rank
ANET Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
ANET Sortino Ratio Rank: 7171
Sortino Ratio Rank
ANET Omega Ratio Rank: 7070
Omega Ratio Rank
ANET Calmar Ratio Rank: 7777
Calmar Ratio Rank
ANET Martin Ratio Rank: 7474
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBIO vs. ANET - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Arista Networks, Inc. (ANET). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BBIOANETDifference
Sharpe ratioReturn per unit of total volatility

+0.46

Sortino ratioReturn per unit of downside risk

+0.53

Omega ratioGain probability vs. loss probability

1.30

1.22

+0.08

Calmar ratioReturn relative to maximum drawdown

3.70

2.16

+1.54

Martin ratioReturn relative to average drawdown

9.25

4.51

+4.74

BBIO vs. ANET - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.60, which is higher than the ANET Sharpe Ratio of 1.15. The chart below compares the historical Sharpe Ratios of BBIO and ANET, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BBIOANETDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.60

1.15

+0.46

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.02

1.01

-0.99

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.95

Sharpe Ratio (All Time)

Calculated using the full available price history

0.16

0.83

-0.66

Drawdowns

BBIO vs. ANET - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, which is greater than ANET's maximum drawdown of -52.20%. Use the drawdown chart below to compare losses from any high point for BBIO and ANET.


Loading charts...

Drawdown Indicators


BBIOANETDifference

Max Drawdown

Largest peak-to-trough decline

-92.80%

-52.20%

-40.60%

Max Drawdown (1Y)

Largest decline over 1 year

-20.25%

-28.33%

+8.08%

Max Drawdown (3Y)

Largest decline over 3 years

-49.08%

-50.42%

+1.34%

Max Drawdown (5Y)

Largest decline over 5 years

-91.89%

-50.42%

-41.47%

Max Drawdown (10Y)

Largest decline over 10 years

-52.20%

Current Drawdown

Current decline from peak

-15.69%

-12.00%

-3.69%

Average Drawdown

Average peak-to-trough decline

-45.80%

-15.40%

-30.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.07%

13.53%

-5.46%

Volatility

BBIO vs. ANET - Volatility Comparison

The current volatility for BridgeBio Pharma, Inc. (BBIO) is 12.10%, while Arista Networks, Inc. (ANET) has a volatility of 16.83%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than ANET based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BBIOANETDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.10%

16.83%

-4.73%

Volatility (6M)

Calculated over the trailing 6-month period

34.41%

40.41%

-6.00%

Volatility (1Y)

Calculated over the trailing 1-year period

46.75%

53.48%

-6.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.95%

47.20%

+38.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.80%

44.99%

+38.81%

Dividends

BBIO vs. ANET - Dividend Comparison

Neither BBIO nor ANET has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

BBIO vs. ANET - Financials Comparison

This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Arista Networks, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B20222023202420252026
180.60M
2.71B
(BBIO) Total Revenue
(ANET) Total Revenue
Values in USD except per share items

BBIO vs. ANET - Profitability Comparison

The chart below illustrates the profitability comparison between BridgeBio Pharma, Inc. and Arista Networks, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
98.8%
61.9%
Portfolio components
BBIO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.

ANET - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Arista Networks, Inc. reported a gross profit of 1.68B and revenue of 2.71B. Therefore, the gross margin over that period was 61.9%.

BBIO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.

ANET - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Arista Networks, Inc. reported an operating income of 1.16B and revenue of 2.71B, resulting in an operating margin of 42.7%.

BBIO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.

ANET - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Arista Networks, Inc. reported a net income of 1.02B and revenue of 2.71B, resulting in a net margin of 37.8%.


Frequently Asked Questions


BBIO and ANET have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ANET has higher volatility (16.83%) compared to BBIO (12.10%). In terms of maximum drawdown, BBIO dropped -92.80% vs ANET's -52.20%.

BBIO currently has the higher Sharpe Ratio (1.60 vs 1.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BBIO and ANET

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer